Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PTC Therapeutics initiates two cancer trials
An open-label Phase Ib clinical trial is expected to enroll up to 42 patients with locally advanced or metastatic solid tumors in order to evaluate the safety and efficacy of
An open-label Phase Ib clinical trial is expected to enroll up to 42 patients with locally advanced or metastatic solid tumors in order to evaluate the safety and efficacy of
The Drs Hans Schreuder scar treatment product is expected to contain soya extract, which is known to even out skin tone and texture. The cream is also expected to
This Phase I trial is designed to evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for Pelizaeus-Merzbacher disease (PMD). Currently, there are no approved
The randomized, double-blind, placebo-controlled, single-center, single ascending dose study is expected to evaluate the safety and pharmacokinetic profile of SPL-017. A total of 74 healthy adult male subjects are expected to be
As part of the restructuring and to further reduce costs, chief development officer, Pierre Etienne; chief commercial officer, Mona Haynes; and, vice president of operations and head of
Beacon has said that the new business relates to the implementation of its recently announced I(3)MAC (innovative, intelligent, installation, move, add, change) infrastructure management platform. Bruce Widener, CEO
The cases were filed by Orthopedic Development Corporation (ODC) and minSURG against NuFix, Nutech and their principals, and involve various claims, including ODC’s claims of infringement of its
In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the brief visuospatial memory
Under the terms of the agreement, Pfizer will receive exclusive rights to commercialize Xiaflex in the 27 member countries of the EU and 19 other European and Eurasian
Study 206 is a double-blind, placebo-controlled, dose range finding, multi- center European Phase IIb trial in about 300 migraineurs who suffer from three or more migraine attacks per